MDM2 and medulloblastoma: In addition to this, RITA must also have reactivated TP53 activity independently of MDM2 and TP53 status, since RITA triggered CDKN1A transcription in medulloblastoma cells harboring either wildtype or mutated TP53. Ultimately, clinical testing of RITA in patients with medulloblastoma is necessary to demonstrate its usefulness therapeutically for the treatment of this highly aggressive pediatric malignancy.